Prospective studies evaluating the occurrence of FGFR2 GAs ab initio and during treatment in patients receiving chemotherapy are therefore warranted to address this issue, as they could open the way for chemotherapy in combination with FGFR inhibitors in selected iCCA patients. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.